GSK is bringing outsourced work back in-house and placing manufacturing at existing sites in a bid to boost efficiency. Big Pharma companies have upped outsourcing in recent years to cut fixed costs ahead of the patent cliff. GlaxSmithKline (GSK), however, is moving some manufacturing and other work back in-house.
